Oppenheimer Maintains Outperform on Merit Medical Systems, Raises Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Steven Lichtman has maintained an Outperform rating on Merit Medical Systems (MMSI) and increased the price target from $82 to $87.
February 29, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained an Outperform rating on Merit Medical Systems and raised the price target from $82 to $87.
The increase in price target by a reputable analyst like Steven Lichtman suggests a strong confidence in Merit Medical Systems' future performance. This is likely to be viewed positively by the market, potentially leading to a short-term increase in MMSI's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100